|
ES2194839T3
(es)
|
1991-07-19 |
2003-12-01 |
Univ Queensland |
Vacuna de papilomavirus.
|
|
EP1835029A1
(en)
|
1992-06-25 |
2007-09-19 |
Georgetown University |
Papillomavirus vaccines
|
|
US5437951A
(en)
*
|
1992-09-03 |
1995-08-01 |
The United States Of America As Represented By The Department Of Health And Human Services |
Self-assembling recombinant papillomavirus capsid proteins
|
|
US20020164350A1
(en)
|
1992-09-03 |
2002-11-07 |
Lowy Douglas R. |
Chimeric papillomavirus-like particles
|
|
US5618536A
(en)
*
|
1992-09-03 |
1997-04-08 |
The United States Of America As Represented By The Department Of Health And Human Services |
Chimeric papillomavirus-like particles
|
|
US8062642B1
(en)
|
1993-03-09 |
2011-11-22 |
University Of Rochester |
Production of papillomavirus capsid protein and virus-like particles
|
|
US6153201A
(en)
*
|
1993-03-09 |
2000-11-28 |
University Of Rochester |
Oral immunization with papillomavirus virus-like particles
|
|
ATE492289T1
(de)
*
|
1993-03-09 |
2011-01-15 |
Univ Rochester |
Herstellung von menschlichen papillomavirus hbv- 11 kapsidprotein l1 und virus-ähnliche partikeln
|
|
GB9306731D0
(en)
*
|
1993-03-31 |
1993-05-26 |
Cancer Res Campaign Tech |
Vaccines
|
|
AU719837B2
(en)
*
|
1993-03-31 |
2000-05-18 |
Cancer Research Campaign Technology Limited |
Pharmaceuticals based on papillomaviruses
|
|
GB2279651A
(en)
*
|
1993-07-01 |
1995-01-11 |
British Tech Group |
Synthetic peptides of human papillomavirus
|
|
GB9313556D0
(en)
*
|
1993-07-01 |
1993-08-18 |
British Tech Group |
Synthetic peptides of human papillomavirus
|
|
AUPM358894A0
(en)
*
|
1994-01-31 |
1994-02-24 |
Csl Limited |
Modified papilloma virus l2 protein and vlps formed therefrom
|
|
DE4415743C2
(de)
*
|
1994-05-04 |
1996-10-10 |
Deutsches Krebsforsch |
Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen
|
|
US5888516A
(en)
*
|
1994-05-16 |
1999-03-30 |
Merck & Co. Inc. |
Recombinant papillomavirus vaccines
|
|
ATE328068T1
(de)
*
|
1994-05-16 |
2006-06-15 |
Merck & Co Inc |
Papillomavirus vakzine
|
|
AUPM566794A0
(en)
*
|
1994-05-17 |
1994-06-09 |
University Of Queensland, The |
Process and product
|
|
IL113817A
(en)
*
|
1994-06-30 |
2001-03-19 |
Merck & Co Inc |
Polynucleotide vaccne for papillomavirus
|
|
AU717647B2
(en)
*
|
1994-10-06 |
2000-03-30 |
Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The |
Chimeric papillomavirus-like particles
|
|
AU717932B2
(en)
*
|
1994-10-06 |
2000-04-06 |
Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The |
Chimeric papillomavirus-like particles
|
|
AU2003235191B2
(en)
*
|
1994-10-07 |
2006-09-21 |
Loyola University Of Chicago |
Papilloma virus-like particles, fusion proteins as well as processes for their production
|
|
DE4435907C2
(de)
*
|
1994-10-07 |
1997-07-24 |
Lutz Prof Dr Gissmann |
Papillomavirusähnliche Partikel und deren Anwendung
|
|
DE19526752C2
(de)
*
|
1995-07-21 |
1997-08-07 |
Lutz Prof Dr Gissmann |
Hocheffiziente Bildung von Papillomavirusähnlichen Partikeln
|
|
DE122007000092I1
(de)
|
1994-10-07 |
2008-03-27 |
Univ Loyola Chicago |
Papillomavirusähnliche partikel, fusionsproteine sowie verfahren zu deren herstellung
|
|
AR004464A1
(es)
*
|
1994-11-14 |
1998-12-16 |
Merck Sharp & Dohme |
Un metodo para producir una proteina de capside de papilomavirus
|
|
JP3958360B2
(ja)
*
|
1995-02-24 |
2007-08-15 |
キャンタブ ファーマシューティカルズ リサーチ リミティド |
免疫治療剤として役立つポリペプチド及びポリペプチド調製の方法
|
|
US5820870A
(en)
*
|
1995-03-22 |
1998-10-13 |
Merck & Co., Inc. |
Recombinant human papillomavirus type 18 vaccine
|
|
IL117459A
(en)
*
|
1995-03-22 |
2005-11-20 |
Merck & Co Inc |
Dna encoding human papillomavirus type 18
|
|
US5840306A
(en)
*
|
1995-03-22 |
1998-11-24 |
Merck & Co., Inc. |
DNA encoding human papillomavirus type 18
|
|
GB9505784D0
(en)
*
|
1995-03-22 |
1995-05-10 |
Lynxvale Ltd |
Anti-tumour treatment
|
|
US5821087A
(en)
*
|
1995-03-30 |
1998-10-13 |
Merck & Co., Inc. |
Production of recombinant human papillomavirus type II protein utilizing papillomavirus 6/11 hybrid DNA
|
|
IL117591A0
(en)
*
|
1995-03-30 |
1996-07-23 |
Merck & Co Inc |
Synthetic DNA encoding human papillomavirus type 11 L1 protein
|
|
SE9501512D0
(sv)
*
|
1995-04-24 |
1995-04-24 |
Euro Diagnostica Ab |
Synthetic peptide-defined eptopes useful for vaccination against papillomavirus
|
|
ATE258222T1
(de)
*
|
1995-11-15 |
2004-02-15 |
Merck & Co Inc |
Synthetische hpv11 virusartige partikel
|
|
US6908615B1
(en)
|
1996-03-18 |
2005-06-21 |
Merck & Co., Inc. |
DNA encoding human papilloma virus type 18
|
|
FR2749323B1
(fr)
*
|
1996-06-04 |
1998-07-10 |
Pasteur Merieux Serums Vacc |
Pseudo-particules virales utiles en tant que vecteur de delivrance d'acide nucleique
|
|
US7118754B1
(en)
|
1996-07-30 |
2006-10-10 |
Transgene S.A. |
Pharmaceutical composition for treating papillomavirus tumors and infection
|
|
FR2751879B1
(fr)
*
|
1996-07-30 |
1998-10-30 |
Transgene Sa |
Composition pharmaceutique contre les tumeurs et infections a papillomavirus
|
|
JP2001506485A
(ja)
*
|
1996-10-04 |
2001-05-22 |
メルク エンド カンパニー インコーポレーテッド |
合成ｈｐｖ１６ウイルス様粒子
|
|
GB9621091D0
(en)
|
1996-10-09 |
1996-11-27 |
Fondation Pour Le Perfectionem |
Attenuated microorganisms strains and their uses
|
|
EP0948351B1
(en)
*
|
1996-12-09 |
2004-02-25 |
Merck & Co., Inc. |
Synthetic hpv16 virus-like particles
|
|
ATE341339T1
(de)
*
|
1996-12-20 |
2006-10-15 |
Merck & Co Inc |
Zusammensetzungen von rekombinanten papillomavirus vakzinen
|
|
AU750702B2
(en)
*
|
1997-05-01 |
2002-07-25 |
Chiron Corporation |
Use of virus-like particles as adjuvants
|
|
CA2295316C
(en)
*
|
1997-07-03 |
2007-06-26 |
University Of Colorado, University Technology Corporation |
Homogeneous human papilloma virus capsomere containing compositions, methods for manufacture, and the use thereof as diagnostic, prophylactic or therapy
|
|
FR2766091A1
(fr)
|
1997-07-18 |
1999-01-22 |
Transgene Sa |
Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee
|
|
US6962777B1
(en)
*
|
1997-09-05 |
2005-11-08 |
Medimmune, Inc. |
In vitro method for disassembly/reassembly of papillomavirus virus-like particles (vlps), homogeneous vlp and capsomere compositions produced by said methods; use thereof as vehicle for improved purification, and delivery of active agents
|
|
US6228368B1
(en)
|
1997-10-06 |
2001-05-08 |
Loyola University Of Chicago |
Papilloma virus capsomere formulations and method of use
|
|
US20020039584A1
(en)
|
1998-02-20 |
2002-04-04 |
Medigene Ag |
Papilloma virus capsomere vaccine formulations and methods of use
|
|
US7494658B2
(en)
|
1998-02-20 |
2009-02-24 |
Medigene Ag |
Papilloma virus truncated L1 protein and fusion protein constructs
|
|
US7182947B2
(en)
|
1998-02-20 |
2007-02-27 |
Medigene Ag |
Papillomavirus truncated L1 protein and fusion protein constructs
|
|
CA2229955C
(en)
|
1998-02-20 |
2003-12-09 |
Medigene Gmbh |
Papilloma virus capsomere vaccine formulations and methods of use
|
|
US6926897B1
(en)
|
1998-03-24 |
2005-08-09 |
Medigene Aktiengesellschaft |
Medicament for the avoidance or treatment of papillomavirus-specific tumour
|
|
US6692752B1
(en)
|
1999-09-08 |
2004-02-17 |
Smithkline Beecham Biologicals S.A. |
Methods of treating human females susceptible to HSV infection
|
|
AUPP765398A0
(en)
|
1998-12-11 |
1999-01-14 |
University Of Queensland, The |
Treatment of papillomavirus infections
|
|
DE19925235A1
(de)
|
1999-06-01 |
2000-12-07 |
Medigene Ag |
Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie
|
|
DE19925199A1
(de)
|
1999-06-01 |
2000-12-07 |
Medigene Ag |
Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie
|
|
DE19925234A1
(de)
*
|
1999-06-01 |
2000-12-14 |
Medigene Ag |
Capsomere, stabile Capsomere, Capside, VLPs, oder CVLPs bzw. damit beladenen Zellen und ihre Verwendung in Diagnostik und Therapie
|
|
GB9921146D0
(en)
*
|
1999-09-07 |
1999-11-10 |
Smithkline Beecham Biolog |
Novel composition
|
|
GB0109297D0
(en)
|
2001-04-12 |
2001-05-30 |
Glaxosmithkline Biolog Sa |
Vaccine
|
|
AUPR446801A0
(en)
|
2001-04-18 |
2001-05-17 |
University Of Queensland, The |
Novel compositions and uses therefor
|
|
KR100785397B1
(ko)
|
2001-06-28 |
2007-12-13 |
아피메즈 주식회사 |
인체 파필로마 바이러스 유사 입자를 생산하는 재조합아데노바이러스 벡터 및 자궁경부암 생백신
|
|
DE10137102A1
(de)
|
2001-07-30 |
2003-02-27 |
Deutsches Krebsforsch |
Polyvalente Vakzine gegen durch Papillomaviren verursachte Erkrankungen, Verfahren zu deren Herstellung und deren Verwendung
|
|
AU2002367977B2
(en)
|
2001-08-13 |
2008-06-19 |
University Of Rochester |
Transcutaneous immunization against papillomavirus with papillomavirus virus-like particles
|
|
CA2457890A1
(en)
*
|
2001-08-23 |
2003-03-06 |
Merck & Co., Inc. |
Vaccine using papillomavirus e proteins delivered by viral vector
|
|
KR20030067873A
(ko)
*
|
2002-02-08 |
2003-08-19 |
주식회사 유니크 |
솔레노이드 밸브
|
|
GB0206360D0
(en)
|
2002-03-18 |
2002-05-01 |
Glaxosmithkline Biolog Sa |
Viral antigens
|
|
ATE500267T1
(de)
|
2003-07-21 |
2011-03-15 |
Transgene Sa |
Multifunktionelle cytokine
|
|
EP1664348B8
(en)
|
2003-09-25 |
2019-06-12 |
Third Wave Technologies, Inc. |
Detection of hpv
|
|
ATE474596T1
(de)
*
|
2004-09-10 |
2010-08-15 |
Asahi Glass Co Ltd |
Impfstoff gegen humanes papillomavirus zur oralen verabreichung
|
|
US8021992B2
(en)
*
|
2005-09-01 |
2011-09-20 |
Taiwan Semiconductor Manufacturing Co., Ltd. |
High aspect ratio gap fill application using high density plasma chemical vapor deposition
|
|
TWI457133B
(zh)
|
2005-12-13 |
2014-10-21 |
Glaxosmithkline Biolog Sa |
新穎組合物
|
|
US8080643B2
(en)
*
|
2006-09-05 |
2011-12-20 |
Third Wave Technologies, Inc. |
HPV primers
|
|
US20090181078A1
(en)
|
2006-09-26 |
2009-07-16 |
Infectious Disease Research Institute |
Vaccine composition containing synthetic adjuvant
|
|
PL2068918T5
(pl)
|
2006-09-26 |
2024-12-02 |
Access To Advanced Health Institute |
Kompozycja szczepionki zawierająca syntetyczny adiuwant
|
|
EP2097517B1
(en)
|
2006-10-16 |
2014-06-04 |
Genelux Corporation |
Recombinant Lister strain vaccinia virus encoding an anti-VEGF single chain antibody
|
|
PL2137210T3
(pl)
|
2007-03-02 |
2017-06-30 |
Glaxosmithkline Biologicals Sa |
Nowy sposób i kompozycje
|
|
EP2479187A1
(en)
*
|
2007-11-23 |
2012-07-25 |
Shanghai Zerun Biotechnology Co., Ltd. |
Genes encoding major capsid protein L1 of human papilloma viruses
|
|
WO2009088256A2
(ko)
*
|
2008-01-09 |
2009-07-16 |
Konkuk University Industrial Cooperation Corp |
배큘로바이러스-기반 백신
|
|
US9623098B2
(en)
|
2008-05-26 |
2017-04-18 |
Cadila Healthcare Limited |
Combined measles-human papilloma vaccine
|
|
GB0815872D0
(en)
|
2008-09-01 |
2008-10-08 |
Pasteur Institut |
Novel method and compositions
|
|
GB0820822D0
(en)
|
2008-11-13 |
2008-12-24 |
Inst Catala D Oncologia |
Novel product and processes
|
|
EP2414512A1
(en)
*
|
2009-04-03 |
2012-02-08 |
Deutsches Krebsforschungszentrum |
Enhanced production of papillomavirus-like particles with a modified baculovirus expression system
|
|
CA2764374C
(en)
|
2009-06-05 |
2019-11-19 |
Infectious Disease Research Institute |
Synthetic glucopyranosyl lipid adjuvants
|
|
CN104288763B
(zh)
|
2009-06-19 |
2018-03-06 |
艾金株式会社 |
宫颈癌疫苗
|
|
WO2011026111A1
(en)
|
2009-08-31 |
2011-03-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Oral delivery of a vaccine to the large intestine to induce mucosal immunity
|
|
EP2556377B1
(en)
|
2010-04-08 |
2017-07-12 |
University of Pittsburgh - Of the Commonwealth System of Higher Education |
B-cell antigen presenting cell assay
|
|
JP6153866B2
(ja)
|
2010-05-25 |
2017-06-28 |
キアゲン ガイサーズバーグ アイエヌシー． |
迅速なハイブリッド捕捉アッセイ、及び関連する戦略的に切断されたプローブ
|
|
KR101349291B1
(ko)
|
2010-08-10 |
2014-01-10 |
한국생명공학연구원 |
고초균을 이용하여 자궁경부암 백신을 제조하는 방법
|
|
EA027236B1
(ru)
|
2011-04-08 |
2017-07-31 |
Иммьюн Дизайн Корп. |
Иммуногенные композиции и способы применения таких композиций для индукции гуморального и клеточного иммунного ответа
|
|
ES2729967T3
(es)
|
2012-02-07 |
2019-11-07 |
Infectious Disease Res Inst |
Formulaciones de adyuvante mejoradas que comprenden agonistas de TLR4 y métodos para usar las mismas
|
|
WO2013139744A1
(en)
|
2012-03-18 |
2013-09-26 |
Glaxosmithkline Biologicals S.A. |
Method of vaccination against human papillomavirus
|
|
HRP20181102T1
(hr)
|
2012-05-16 |
2018-09-07 |
Immune Design Corp |
Cjepiva za hsv-2
|
|
EP3587455A1
(en)
|
2012-10-23 |
2020-01-01 |
Emory University |
Gm-csf and il-4 conjugates, compositions, and methods related thereto
|
|
MX370573B
(es)
|
2013-04-18 |
2019-12-17 |
Immune Design Corp |
Monoterapia con glucopiranosil lipido a para usarse en el tratamiento del cancer.
|
|
US9463198B2
(en)
|
2013-06-04 |
2016-10-11 |
Infectious Disease Research Institute |
Compositions and methods for reducing or preventing metastasis
|
|
IL310015B2
(en)
|
2013-12-31 |
2026-02-01 |
Access To Advanced Health Inst |
Single vial formulation
|
|
US10314906B2
(en)
|
2015-03-18 |
2019-06-11 |
University Of Massachusetts |
Virus-like particle compositions and vaccines against Epstein-Barr virus infection and disease
|
|
KR101908438B1
(ko)
*
|
2016-02-05 |
2018-10-16 |
(주)피앤피바이오팜 |
Arsntd를 융합파트너로 이용한 수용성 및 활성형 재조합단백질의 생산방법 및 그 생산물
|
|
JP7005504B2
(ja)
|
2016-02-22 |
2022-01-21 |
ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー |
生体分子の固定化方法
|
|
MX2018014086A
(es)
|
2016-05-16 |
2019-09-18 |
Infectious Disease Res Inst |
Formulacion que contiene agonista tlr y metodos de uso.
|
|
WO2017200957A1
(en)
|
2016-05-16 |
2017-11-23 |
Infectious Disease Research Institute |
Pegylated liposomes and methods of use
|
|
KR20250008135A
(ko)
|
2016-06-01 |
2025-01-14 |
액세스 투 어드밴스드 헬스 인스티튜트 |
사이징제를 함유하는 나노명반 입자
|
|
MX2019015076A
(es)
|
2017-06-15 |
2020-08-03 |
Infectious Disease Res Inst |
Portadores lípidos nanoestructurados y emulsiones estables y usos de los mismos.
|
|
WO2019051149A1
(en)
|
2017-09-08 |
2019-03-14 |
Infectious Disease Research Institute |
LIPOSOMAL FORMULATIONS COMPRISING SAPONIN AND METHODS OF USE
|
|
RU2681174C1
(ru)
*
|
2018-07-12 |
2019-03-04 |
Закрытое акционерное общество научно-производственная компания "Комбиотех" |
Способ получения рекомбинантной вакцины для профилактики папилломавирусной инфекции человека, рекомбинантная вакцина
|
|
CA3141577A1
(en)
|
2019-05-25 |
2020-12-03 |
Infectious Disease Research Institute |
Composition and method for spray drying an adjuvant vaccine emulsion
|
|
JP7017811B2
(ja)
*
|
2020-02-13 |
2022-02-09 |
国立研究開発法人農業・食品産業技術総合研究機構 |
ウイルス様粒子及びその使用
|
|
WO2022051022A1
(en)
|
2020-09-04 |
2022-03-10 |
Infectious Disease Research Institute |
Co-lyophilized rna and nanostructured lipid carrier
|
|
MX2023009456A
(es)
|
2021-02-11 |
2023-08-28 |
Glaxosmithkline Biologicals Sa |
Preparacion de la vacuna contra el vph.
|
|
US20250066835A1
(en)
*
|
2021-12-29 |
2025-02-27 |
Hitachi High-Tech Corporation |
Microbial Image Analysis Method
|
|
CA3266697A1
(en)
|
2022-09-09 |
2024-03-14 |
Access To Advanced Health Institute |
COMPOSITION OF AN IMMUNOGENEOUS VACCINE CONTAINING A SAPONIN
|